Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

NCT03384316 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

11

Enrollment

NIH

Sponsor class

Conditions

Neoplasms
Prostate Cancer
Lung Cancer
Breast Cancer
Colon Cancer

Interventions

BIOLOGICAL: ETBX-051; adenoviral brachyury vaccine
BIOLOGICAL: ETBX-061; adenoviral Mucin-1 (MUC1) vaccine
BIOLOGICAL: ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine

Sponsor

National Cancer Institute (NCI)